. A key feature of S. aureus disease is its recurrence, which occurs for 8-33% of cases of SSTI and bloodstream infections 3 . Prior disease does not elicit protection against subsequent S. aureus infection 2 . Neutrophils play a central part in protecting humans against S. aureus infection. Staphylococcal entry and replication in host tissues leads to the release of bacterial products (formyl-peptides, lipoproteins or peptidoglycan) and to damaged tissues that produce inflammatory signals (that is, chemoattractants and cytokines 4 ). Staphylococcal products are detected by immune cells via Toll-like receptors (TLRs) and G protein-coupled receptors, whereas cytokines activate cognate immune receptors. Neutrophils answer this call, extravasate from blood vessels, and migrate towards the site of infection to phagocytose and kill bacteria or to immobilize and damage the pathogen through NETosis -the release of neutrophil extracellular traps (NETs) comprising DNA and antimicrobial peptides 4 . The importance of neutrophils in controlling S. aureus infection has been documented through the study of immune defects. Mutations in genes encoding NADPH oxidase, the enzyme generating bactericidal superoxide in phagocytes, cause chronic granulomatous disease (CGD), which is associated with defects in phagocytic killing of S. aureus and frequent infection 5 . Individuals with inborn errors of signal transducer and activator of transcription 1 (STAT1) or STAT3 signalling of immune cells have perturbed interleukin-17 (IL-17) cytokine pathways, which diminishes mucocutaneous immunity and promotes S. aureus infection 6 . IL-17-dependent T cell signalling is a key activator of neutrophils and of anti-staphylococcal defences 7 . Finally, cancer patients with diminished blood neutrophil counts are highly susceptible to S. aureus infection 8 . Nevertheless, the vast majority of S. aureus disease occurs in immune-competent individuals without defects in phagocyte function. To achieve this, S. aureus deploys an arsenal of immune-evasive strategies that together prevent phagocytosis and killing by neutrophils. Furthermore, the ability of the pathogen to cause
Abscesses
The pathological product of Staphylococcus aureus infection: the harbouring of a staphylococcal abscess community within a pseudocapsule of fibrin deposits that is surrounded by layers of infiltrating immune cells destroying physiological organ tissue.
Superantigen
Molecules that crosslink B cell receptors (that is, IgM) or T cell receptors and major histocompatibility complexes to trigger lymphocyte proliferation, thereby diverting adaptive immune responses.
Anaphylatoxin
Protein fragments generated during complement activation of C3a and C5a that trigger immune responses via C3a and C5a receptors on immune cells. recurrent disease implies the presence of mechanisms that effectively block the development of adaptive immune responses. Here, we review recent work on the immune evasive attributes of S. aureus, including the subversion of the innate and adaptive immune systems and the killing of immune cells, along with epidemiological features of the corresponding genes. We also discuss how the characterization of bacterial immune evasive factors can have translational effects in the therapy of autoimmune diseases or the development of vaccines and immunotherapeutics against S. aureus infection.
Subversion of innate immune responses
Neutrophil extravasation and chemotaxis. Proinflammatory signals promote neutrophil adhesion and extravasation across capillary endothelia, relying on reciprocal interactions between endothelial receptors (such as P-selectin, E selectin, intercellular adhesion molecule 1 (ICAM1) and hyaluronan) and ligands on neutrophil surfaces (such as P-selectin glycoprotein ligand 1 (PSGL1), lymphocyte function-associated antigen 1 (LFA1; also known as αLβ2 integrin), αMβ2 integrin and CD44) 9 . Although neutrophils function to migrate towards bacterial invaders, S. aureus can interfere with neutrophil extravasation and chemotaxis through the secretion of staphylococcal superantigen-like proteins (SSLs), phenol-soluble modulins (PSMs), chemotaxis inhibitory protein of S. aureus (CHIPS), formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like (FLIPrL).
SSLs are a family of secreted proteins with structural homology to staphylococcal superantigens [10] [11] [12] . The ssl genes are arranged as tandem repeats in genomic island-α (GIα; for ssl1-ssl11) and in the immune evasion cluster 2 (IEC2; for ssl12-ssl14) on the bacterial chromosome 13 . GIα-encoded ssl genes vary between lineages as does the coding sequence of individual ssl genes; the number of different alleles ranges from 1 to 13 and most alleles are uniquely associated with specific S. aureus lineages 13 . ssl1, ssl2, ssl3, ssl11, ssl12, ssl13 and ssl14 are found in all S. aureus isolates 13 
. Purified, recombinant SSL5 and SSL11 bind PSGL1 on leukocytes and, when assayed in vitro, interfere with the binding of neutrophils to P-selectin and neutrophil adhesion and rolling 14, 15 (FIG. 1a) .
SSL5 also interferes with chemokine-and a naphylatoxinmediated activation of neutrophils by binding to the glycosylated amino termini of G protein-coupled receptors 14, 16 . Moreover, SSL5 has been shown to activate platelets and support their adhesion involving platelet surface receptors GPIbα and GPVI 17, 18 . Intravenous administration of SSL5 caused intravascular platelet-rich thrombi and increased bleeding of C57Bl/6 mice 19 . Other work demonstrated SSL5-mediated inactivation of leukocyte matrix metalloproteinase 9 (REF. 20 ). The affinity of SSL5 for different host factors is mediated via its glycan binding pocket, an attribute that is shared by other members of the SSL family 21 . SSL3 binds to TLR2 and blocks immune cell recognition of staphylococcal lipoproteins and peptido glycan via TLR1-TLR2 and TLR2-TLR6 hetero dimers 22 , and SSL10 blocks C-X-C chemokine receptor 4 (CXCR4)-mediated
Box 1 | Variability of Staphylococcus aureus immune evasion determinants
Genome sequencing of Staphylococcus aureus isolates from humans and animals has provided insights into the origin, diversification and spread of the pathogen. Over the past 10,000 years, S. aureus evolved as a colonizer and pathogen of humans and their lifestock 142 , generating lineages with unique genetic traits and discrete host ranges 143 . Staphylococcal evolution was accompanied by the loss of genes encoding the CRISPR-Cas system, which protect the genome against phages and mobile genetic elements. S. aureus relies on horizontal gene transfer mediated by these elements for adaptation, and it preserves its identity through restriction modification systems and satellite phage-encoded pathogenicity islands that block phage replication 143 . When placed under selection in different hosts, S. aureus acquires mobile genetic elements that contain genes for antibiotic resistance, immune evasion and adhesion to specific anatomic niches. Analysis of large genome datasets described the core genome, which is common to all S. aureus isolates, and found that these core genes contribute to colonization, tissue invasion, establishment of abscess lesions, dissemination, immune evasion and pathogenesis of reiterative disease 36 . Variable genes are associated with S. aureus colonization or invasion of specific host species or may be present in subsets of strains associated with increased virulence or specific disease (for example, enterotoxin-mediated gastroenteritis) 93 . Generally, capsular polysaccharide and cell wall-anchored surface proteins are components of the core genome and contribute to immune evasion by synthesizing adenosine (by adenosine synthase A), binding fibrinogen or fibrin (by clumping factors A and B and fibronectin binding proteins A and B) and binding immunoglobulin (by staphylococcal protein A (SpA)). Several secreted proteins are components of the core genome: proteases that cleave host factors (such as aureolysin and staphopain), coagulases that activate prothrombin (such as coagulase and von-Willebrand factor binding protein), toxins that lyse immune cells (such as γ-haemolysin AB, γ-haemolysin CB and leukocidin AB), inhibitors of host proteases (staphylococcal extracellular adherence protein and its homologues) and phenol-soluble modulins, peptides that perturb host cell membranes and trigger neutrophil chemotaxis. Genetic determinants that interfere with neutrophil chemotaxis, phagocytosis, complement activation, promote lysis of immune cells or activate T cells often represent constituents of the variable genome. . CC75 strains lack the staphyloxanthin gene cluster, retain the CRISPR-Cas system and lack S. aureus pathogenicity islands (SaPIs), but they are endowed with genomic island-α and genomic island-β, a unique coa gene and a unique spa sequence type, which are elements important for staphylococcal evasion of innate and adaptive immune responses 144 . These strains, with the species designation Staphylococcus argenteus, may represent an early and terminal branch in the development of S. aureus in which mobile genetic elements were not incorporated into the genome because the retained CRISPR-Cas system prevented horizontal gene transfer 144 .
Enterotoxin
A staphylococcal superantigen that crosslinks major histocompatibility complex class II molecules and T cell receptors, thereby triggering T cell proliferation, anergy and cytokine storms.
Opsonization
Deposition of complement components on bacterial surfaces to promote recognition, phagocytosis and killing by host phagocytes.
responses on lymphocytes, interfering with the chemoattraction of neutrophils 4 (FIG. 1a) . Recent work suggests that SelX, a staphylococcal enterotoxi n (superantigen)-like protein, also binds glycosylated PSGL1, and that SSL6 binds to CD47 (also known as integrin-associated protein), a common receptor on most host tissues that promotes migration, anti-phagocytosis and proliferation 23 . Thus, SSLs presumably associate with a wide range of glycoproteins on leukocytes and/or platelets to implement immune-evasive attributes. Most SSLs display species specificity for human but not animal host factors, and SSL-mediated contributions towards S. aureus pathogenesis cannot be measured in animal experiments. S. aureus also inhibits leukocyte migration via the extracellular adherence protein (Eap). Eap is composed of four β-grasp-like domains and associates with ICAM1 to inhibit leukocyte migration 24 . The eap gene is located in the eap-hlb locus, the attachment site for hlb-converting phages carrying the IEC1 gene cluster 13 
.
PSMs are a family of short formyl-peptides that are secreted via an ABC transporter and interfere with the physiological functions of immune cells, specifically neutrophils 25 . PSMα1-PSMα4 and PSMβ1, and PSMβ2, whether formylated or not, activate formyl-peptide receptor 2 (FPR2) on human and mouse neutrophils and stimulate cytokine release 26 . Of note, PSMα1-PSMα4 and PSMβ1 and PSMβ2 are neutralized by binding to serum lipoproteins, and reactive oxygen species (ROS) of activated neutrophils are reported to neutralize PSM signalling 27 . Recent work demonstrated that PSMα3N22Y, a variant with diminished FPR2-binding activity that is secreted by the clonal complex 30 (CC30) methicillinresistant S. aureus (MRSA) lineage, is associated with diminished FPR2 signalling and diminished cytotoxicity, while enhancing bacterial replication and the establishment of abscess lesions in renal tissues 28 . The activation of FPRs via the formyl moiety of PSMs and via their direct binding to FPR2 stimulates chemotaxis. Thus, a key attribute of formylated PSMs seems to be the stimulatio n of neutrophil chemotaxis via FPRs.
S. aureus also counters neutrophil chemotaxis, which occurs via the secretion of CHIPS, FLIPr and FLIPrL 4 (FIG. 1a) . CHIPS is encoded by the chp gene in IEC1, which is carried on hlb-converting phages 29 . chp is found in most human S. aureus isolates but not in livestockassociated strains 13 . Secreted CHIPS binds to human formyl-peptide receptor 1 (FPR1) and human C5aR, the complement receptor of neutrophils, but not to mouse FPR1 or C5aR 30, 31 . FLIPr and FLIPrL are encoded by genes in the IEC2 locus; at least 9 different alleles are known for these genes, which are found in many, but not all, human S. aureus isolates 13 
. FLIPrL inhibits FPR1 signalling, whereas FLIPr and FLIPrL bind to FPR2 and inhibit its receptor signalling function 32, 33 . Finally, staphopain (ScpA), a secreted cysteine protease, cleaves CXCR2-binding chemokines to block neutrophil migration towards staphylococci 34 (FIG. 1a) . The lifestyle of S. aureus -invasion of host tissues, replication in abscess lesions and dissemination upon purulent drainage of lesions -requires recruitment of immune cells to the site of infection 35, 36 . However, staphylococcal products manipulate infiltrating immune cells to limit their capacity for chemotaxis, phagocytosis and bacterial killing, thereby ensuring the successful outcome of infection.
Complement activation and phagocytosis. Complement, a key component of innate host defences, is composed of >30 proteins that have broad functions in host defence against microorganisms, inflammation, haemostasis and wound repair. Complement is activated by any one of three routes: the classical pathway (which entails antibody and C1q deposition on the staphylococcal surface), the lectin pathway (which involves the association of mannose-binding lectin (MBL)-MBL-associated serine protease (MASP) complexes with staphylococcal carbohydrates) and the alternative pathway (which involves spontaneous breakdown of the complement protein C3 in the serum). The three pathways converge in the assembly of a C3 convertase (C4b2a for the classical and lectin pathways, and C3bBb for the alternative pathway). C3 convertase cleaves C3 into C3a and C3b; C3b becomes covalently linked to the staphylococcal surface (known as opsonization), and C3a is released as a chemoattractant for phagocytes 37 . At high local concentrations of C3b, the C5 convertase cleaves C5 into C5a, another chemoattractant, and C5b, the surface deposition of which promotes membrane attack complex (MAC) formation 37 . The MAC is effective at killing Gram-negative bacteria; however, it is not effective against S. aureus, which has a thick peptidoglycan layer that prevents access to the bacterial membrane 38 . In addition to the thick peptidoglycan layer, many clinical S. aureus strains express genes for the production of one of two types of capsular polysaccharide, type 5 or type 8 (REF. 39 ). In vitro phagocytosis assays suggested that capsule expression protects staphylococci from neutrophil phagocytosis in the presence of opsonins, and that capsule expression contributes to the pathogenesis of S. aureus infection in mice 39 . Capsule-induced protection from phagocytosis may be strain specific, as capsule mutations in other S. aureus isolates do not affect the pathogenesis of bloodstream infections in mice 36 . USA300, the current pandemic clone of communityacquired MRSA infections, carries a mutation that abrogate s capsule expression 40 (TABLE 1).
S. aureus secretes several proteins that interfere with the deposition of complement on the bacterial surface (FIG. 1b) . Aureolysin, a secreted zinc-dependent metalloproteinase, cleaves C3 to generate functionally active C3a and C3b. Complement factor I (fI) and factor H (fH) degrade or bind C3b, which prevents its accumulation on the staphylococcal surface 41 . The aureolysin gene, aur, is polymorphic and specific alleles are associated with different S. aureus lineages. An in vivo phenotype for S. aureus aur mutants has not yet been described.
Staphylococcal complement inhibitor (SCIN) associates with and inhibits C3 convertase (C3bBb), thereby preventing the production of C3a, C3b and C5a and interfering with complement activation 42 (FIG. 1b) . The structural gene for SCIN, scn, is also located on hlbconverting phages together with chp and sak (which encodes staphylo kinase, see below). Two polymorphic 
FcαRI
The IgA Fc receptor, which regulates mucosal immune responses in humans.
Fcγ domain
The portion of antibodies dedicated to C1q complement and Fc-receptor activation.
Core genome
The portion of the genome shared by all members of a bacterial species.
homologues of SCIN, designated SCIN-B and SCIN-C, are encoded by genes in the IEC2 locus. scn, scnB and scnC are found in many, but not all, human clinical isolates
; SCIN, SCIN-B and SCIN-C associate with C3 convertase from humans but not with that of other vertebrates 43 . The genes encoding extracellular fibrinogenbindin g protein (Efb) and its homologue, extracellular c omplement-binding protein (Ecb), are also located on IEC2. Both Efb and Ecb bind to C3d (a cleavage product of C3b that activates innate and adaptive responses by binding to complement receptor 2 (CR2)) and inhibit C3bBb and the C5 convertases 43, 44 (FIG. 1b) . Ecb associates with both fH and C3b to facilitate the complement inhibitory attributes of fH 45 . Efb also binds fibrinogen and prevents fibrinogen interaction with αMβ2, an integrin on neutrophils that activates pro-inflammatory responses, as well as fibrinogen-mediated platelet activation 46, 47 . Efb and Ecb inhibitory activities have been observed for human and mouse convertases and fibrinogen. In the mouse intravenous challenge model, the S. aureus ΔefbΔecb mutant displayed reduced time-to-death and increased survival, as well as diminished abscess formation in organ tissues 48 . The ecb gene is found in all S. aureus genomes sequenced to date, whereas efb is found in many, but not all, human clinical isolates 13 . SSLs also interfere with complement activation and phagocytosis. For example, SSL7 binds to human IgA and complement C5, interfering with IgA binding to FcαRI, the production of C5a and the oxidative burst of phagocytes in vitro; the in vivo contributions of SSL7 towards S. aureus pathogenesis are not known 49 . SSL10 binds to human and non-human primate IgG1, but not to immunoglobulins of lower vertebrates, and inhibits IgG1 binding to Fcγ receptors and the in vitro phagocytosis of IgG1-opsonized bacteria by immune cells 50, 51 . Staphylococcal binder of immunoglobulin (Sbi) is a secreted protein with two immunoglobulin binding domains (IgBDs; designated Sbi-I and Sbi-II), which are triple-helical bundles that associate with the Fcγ domain of human and vertebrate immunoglobulin
. Sbi-I and Sbi-II interfere with C1q binding to immunoglobulin and block the classical complement pathway 52, 53 (FIG. 1b) .
The Sbi-III and Sbi-IV domains associate with C3 and fH to form tripartite complexes that inhibit the alternative pathway 54, 55 (FIG. 1b) . The sbi gene is located in the sbi-hlg locus of the core genome of all isolates 13 . Staphylokinase forms enzymatically active complexes with plasminogen, cleaving fibrin, defensins, human IgG, C3b and its proteolytically inactivated product iC3b on bacterial surfaces, thereby blocking complement activation [56] [57] [58] (FIG. 1b) .
Collagen adhesin (Cna), a surface protein expressed by some S. aureus isolates, binds C1q and interferes with classical pathway activation, blocking the association between C1q and C1r
.
Neutrophil-mediated killing. Once phagocytosed, staphylococci are exposed to a variety of toxic products that kill and degrade the engulfed bacteria: antimicrobial peptides, nitric oxide (NO), ROS (that is, hydrogen peroxide, superoxide and hydroxyl radicals), cell wall hydrolases and proteolytic enzymes 4 . However, S. aureus has evolved a number of strategies to survive in this environment (FIG. 1c) . Peptidoglycan acetylation (by the protein OatA), d-alanylation of teichoic acids (by the DltABCD complex), and lysyl-or alanyl-phosphatidylglycerol synthesis (by the protein MprF) provide staphylococcal resistance against lysozyme-and antimicrobial peptide-mediated killing by blocking enzymes (such as lysozyme) or peptides binding to the envelope target [60] [61] [62] . Staphyloxanthin, a carotenoid pigment synthesized by all S. aureus isolates 63 , provides resistance against hydrogen peroxide and/or hydroxyl radicals, the bactericidal compounds of neutrophils 64 (this is not the case for CC75 isolates but we consider these to belong to a separate species, Staphylococcus argenteus
). Similarly, two superoxide dismutases (SodA and SodM), fulfill overlapping functions in eliminating neutrophil super oxide 65 , whereas catalase (KatG) and alkylhydroper oxide reductase (AhpC) protect staphylococc i against hydrogen peroxide 66 . Figure 1 | Staphylococcus aureus interference with chemotaxis, complement and killing by phagocytes. a | Neutrophil extravasation and chemotaxis is inhibited by Staphylococcus aureus through the secretion of staphylococcal superantigen-like (SSL) molecules. SSL3 inhibits Toll-like receptor (TLR) heterodimers, SSL5, SSL11 and SelX inhibit PSGL1 signalling (SSL11 is not shown), and SSL6 inhibits the G protein-coupled receptor CD47. Other secreted proteins include chemotaxis inhibitory protein of S. aureus (CHIPS), which inhibits the complement receptor C5aR and formyl-peptide receptor 1 (FPR1) and FPR2, formyl peptide receptor-like 1 inhibitor (FLIPr) and FLIPr-like (FLIPrL), which inhibit FPR1 and FPR2, and staphopain, which inhibits signalling from the chemokine receptor C-X-C chemokine receptor (CXCR2). b | Complement activation and phagocytosis of staphylococci are blocked through the secretion of inhibitory factors that interfere with opsonization. Collagen adhesin (Cna) blocks the association of complement factor C1q bound to immunoglobulin with complement receptor C1r. Staphylococcal protein A (SpA) and staphylococcal binder of immunoglobulin (Sbi) binding to immunoglobulin blocks its association with C1q. Sbi, SpA, SSL7 and SSL10 sequester immunoglobulins to block their ability to promote complement activation. Sbi (when associated with the host factors C3d and factor H (fH)) and SSL7 also inactivate the complement factors C3 and C5, respectively. Sak associates with plasminogen (PLG) and activates the zymogen to cleave complement factor C3b and immunoglobulin. Extracellular complement-binding protein (Ecb), extracellular fibrinogen-binding protein (Efb), staphylococcal complement inhibitor (SCIN) and extracellular adherence protein (Eap) inhibit C3 convertases, and aureolysin (Aur) cleaves the complement factor C3, which compromises opsonization because the cleavage product C3b is degraded by a complex of the host proteins fI and fH. c | S. aureus inhibits neutrophilmediated killing of phagocytosed bacteria by expressing several enzymes and inhibitors. The adenosine-synthesizing enzyme AdsA enables the inhibition of granulation via adenosine receptor (AdoR) signalling. Staphyloxanthin, superoxide dismutase A (SodA) and SodM, the catalase KatG and alkylhydroperoxide reductase (AhpC) are antioxidants that reduce oxidative stress caused by phagosomal reactive oxygen species (ROS) and H 2 O 2 generation. Aureolysin (Aur) cleaves antimicrobial peptides and DltA-DltD promote d-alanyl esterification of teichoic acids to protect staphylococci from antimicrobial peptides. MprF modifies phosphatidylglycerol with alanine or lysine, another mechanism to protect staphylococci against antimicrobial peptides. l-lactate dehydrogenase (Ldh) and flavohaemoglobin (Hmp) inhibit nitrosative stress, Eap and its homologues EapH1 and EapH2 inhibit neutrophil serine proteases, and OatA O-acetylates peptidoglycan, which prevents its lysozymal degradation. d | Secreted β-barrel pore forming toxins (β-PFTs) bind specific receptors on immune cells to impair immune cell functions or promote cell lysis. These β-PFTs include leukocidin ED (LukED) (which binds to neutrophils, T cells and macrophages), γ-haemolysin AB (HlgAB) (which binds to neutrophils, macrophages and red blood cells), HlgCB and Panton-Valentine leukocidin (PVL) (which bind to neutrophils and macrophages), and LukAB and α-haemolysin (Hla) (which bind to neutrophils). Phenol-soluble modulin-α (PSMα), which is another factor secreted by S. aureus (but not a β-PFT), can also lyse leukocytes.
◀
In response to nitrosative stress, S. aureus expresses flavo haemoglobin (Hmp), which detoxifies NO, and l-lactate dehydrogenase, which maintains redoxhaemostasi s and survival within neutrophils by producing l-lactate 67 . In addition to its role in inhibiting complement activation, Eap and two structural homologues, EapH1 and EapH2 (which do not inhibit complement), promote S. aureus survival by inhibiting neutrophil serine proteases (such as elastase, cathepsin G and proteinase 3) 68 .
In the intravenous mouse challenge model, the S. aureus Δeap mutant displays a moderate virulence defect 36 ; however, the ΔeapΔeapH1ΔeapH2 mutant displays reduced bacterial load and increased mouse survival 68 .
Staphylococcal killing of host cells. In addition to its ability to inhibit phagocyte-mediated killing, S. aureus also manipulates innate immune responses by inducing the killing of innate immune cells via PSMs and different toxins (FIG. 1d) . The PSMα locus includes psma1-psma4, whereas PSMβ includes psmb1 and psmb2; psmb2 is found in only some, but not all, S. aureus strains 13 . Peptides similar to PSMα1-PSMα4 and PSMβ1 are expressed by Staphylococcus epidermidis, a commensal of the human skin that cannot cause abscess lesions or bloodstream infections in immune competent individuals 25 . Mutations that delete psma1-psma4 and psmb1 and psmb2 interfere with in vitro biofilm formation of S. aureus mutants and with the expression of virulence factors, including α-haemolysin 25 . S. aureus Δpsma1-psma4 mutants are attenuated in the mouse bloodstream infection model 69 , a phenotype that may be due to defects in biofilm formation, virulence gene expression and/or contributions of PSMα1-PSMα4 towards lysis of immune cells, presumabl y via membrane insertion and pore formation 70 . β-barrel pore-forming toxins (β-PFTs) are secreted by the bacterium as soluble monomers and, on association with receptors on cell surfaces, assemble into multimeric pore structures, penetrating the lipid bilayer to invoke alterations in the physiology of injured cells or their outright lysis 71 . α-haemolysin (Hla), the prototype β-PFT of S. aureus, is encoded by the hla gene, which is located within IEC2. Although conserved among all S. aureus isolates, some lineages of S. aureus carry a nonsense mutation that blocks hla expression 72 . Hla binds to its receptor on host cells, ADAM10, and assembles into a heptameric pore; through the metalloproteinase activity of ADAM10, Hla modulates the function of immune cells, including neutrophils, or triggers lysis of epithelial cells 73, 74 . S. aureus hla mutants display defects in disease severity in mouse models for lethal pneumonia, bacteraemia and SSTI; however, hla is not required for the establishment of S. aureus abscess lesions [75] [76] [77] . Based on ADAM10 expression on the surface of myeloid cells, organ epithelia and the vascular endothelium, Hla causes global, as well as organ-specific, changes to host physiolog y during S. aureus infection 74 .
Leukocidins are other β-PFTs secreted by S. aureus (FIG. 1d) . Following leukocidin association with receptors on myeloid cells and erythrocytes, these toxins assemble from two different subunits (F and S) into an octameric pore structure 78 . All S. aureus strains produce at least three leukocidins, γ-haemolysin AB (HlgAB), HlgCB and leukocidin AB (LukAB; also known as LukGH), whereas other strains may also secrete Panton-Valentine leucocidin (PVL; which is encoded by lukPV) and LukED or LukMF 79
. The operon encoding LukAB is located immediately adjacent to hlb, whereas the operon encoding γ-haemolysin (hlgABC) is part of the sbi-hlg locus. LukAB binds to the I domain of human, but not mouse, αM integrin on myeloid cells 80 . Purified LukAB can trigger human neutrophils to release NETs that, at least temporarily, ensnare staphylococci 81 . LukAB has also been reported to promote S. aureus escape from the phagosome of neutrophils 82 . Purified HlgAB γ-haemolysin, but not purified HlgCB γ-haemolysin, is able to lyse human and rabbit red blood cells 83 . HlgAB binds to chemokine receptors CXCR1, CXCR2 and CC-chemokine receptor 2 (CCR2), whereas HlgCB uses complement receptors C5aR and C5L2 to associate with target cells 84 . Following staphylococcal inoculation into human blood, hlgABC is upregulated 34-145-fold 85 , and the S. aureus ΔhlgABC mutant displays reduced survival, presumably because HlgAB and HlgCB promote release of iron-compounds from erythrocytes, thereby enabling bacterial acquisition of this essential nutrient 83 . 
Sortase
The bacterial transpeptidase responsible for anchoring surface proteins to the cell wall envelope.
Both purified HlgAB and HlgCB promote lysis of neutrophils, monocytes and macrophages from humans, as well as non-human primates, and to a lesser degree rabbits and mice 83 . In a mouse intravenous challenge model, animals infected with a S. aureus ΔlukAB mutant displayed increased time-to-death and survival. Using subcutaneous inoculation in mice or rabbits, the S. aureus lukAB mutant did not display defects in skin abscess formation 86 . The ΔhlgAB mutant displayed a virulence defect in the intraperitonea l challenge model in mice 84 . lukED is present in the GIβ locus of ~70% of clinical S. aureus isolates 13 
. Purified LukED triggers lysis of macrophages, dendritic cells and T cells from many different vertebrates, as the toxin binds to the chemokine receptors CCR5, CXCR1 and CXCR2 (REFS 87,88). For S. aureus strain Newman, which harbours GIβ, the ΔlukED mutation increased the time-to-death and survival of mice following intravenous challenge with mutant staphylococci 89 . PVL is secreted by S. aureus lysogenized with PVL phage 90 . PVL binds to the C5aR on neutrophils, monocytes and macrophages, but its activity is restricted towards human and rabbit cells 9 . By virtu e of binding C5aR, PVL not only exerts its lytic activity on target host cells but can also facilitate the priming of human polymorphonuclear leukocytes by pro-inflammatory stimuli (for example, formyl peptides). Injection of purified recombinant PVL leads to increased immune cell recruitment and increased architectural destruction of the lung, owing to toxin-mediate d recruitment and subsequent lysis of immune cells 9 . Only ~2% of S. aureus isolates secrete PVL; however, community-acquired MRSA isolates frequently harbour PVL phages, and PVL expression is also associated with necrotizing pneumonia 91 . S. aureus ΔlukPV variants display defects in the pathogenesis of SSTIs and lung infections in rabbits, but not in mice, which seems to be due to neutrophil-mediated inflammatory responses and tissue distruction 76, 92 . lukMF, genes for another phageencoded leukocidin, are found in S. aureus isolate s associate d with bovine mastitis 13 . Staphylococcal agglutination. Coagulation, the conversion of fibrinogen to a crosslinked fibrin meshwork by activated thrombin, is an innate defence of all vertebrates that immobilizes microbial invaders and attracts immune cells for phagocytic clearance of bacteria. Therefore, every successful bacterial pathogen must evolve mechanisms for escape from fibrin entrapment and subsequent phagocytosis by infiltrating immune cells. A hallmark of all S. aureus isolates is the secretion of two coagulases: coagulase (Coa) and von Willebrand factor-binding protein (vWbp) 93 . Coa and vWbp associate with prothrombin, a zymogen, to generate enzymatically active staphylothrombin, which cleaves the A and B peptides of fibrinogen to generate fibrin fibrils 94 (FIG. 2) . As staphylothrombin does not cleave other substrates of thrombin, it avoids the activation of clotting and inflammatory factors that ordinarily accompany fibrin polymerization 95 . Staphylothrombin activity is not subject to feedback inhibition through host antithrombin. However, staphylothrombin is blocked by dabigatran and other direct thrombin inhibitors of the same family 96 . The staphylothrombin-generated fibrin meshwork protects S. aureus from phagocytes and contributes to the formation of staphylococcal abscess lesions and lethal bacteraemia in mice 97 . Activation of prothrombin is mediated by the D1 and D2 domains in the N-terminal region of Coa and is blocked by specific antibodies, which provide protection from S. aureus bloodstream infection in the mouse model 98 . Perhaps owing to purifying selection, coa is one of the most variable genes in the core genome of S. aureus, with >50% sequence variation in the coding sequence for its D1-D2 domains and 14 distinct isoforms 93 (TABLE 1) . vWbp also has conserved D1-D2 domains for association with prothrombin, but this complex generates fibrin at a reduced rate and contributes to abscess formation without affecting staphylococcal escape from phagocytosis 99 . The gene encoding vWbp, vwb, has limited sequence variability 98 . S. aureus agglutinates with Coa-or vWbp-derived fibrin fibrils, which requires clumping factor A (ClfA), a glycosylated, sortase-anchored surface protein, the immunoglobulin-like domains of which bind to
Box 2 | Structural features of immune evasion factors
Crystallographic analysis of Staphylococcus aureus immune evasion determinants revealed five discrete structural domains that enable specific interactions with the host's immune system: oligonucleotide-binding (OB) fold, β-grasp domain, triple-helical bundle (THB), leukocidin domain and immunoglobulin-like fold. Varying the amino acid sequence for these domains has created panoplies of ligands that interact with the defence molecules of infected hosts at the places that matter most 4, 145 . Thus, the study of S. aureus immune evasion factors laid bare the most intricate workings of the human immune system and identified new avenues for the therapy of autoimmune and inflammatory diseases. Examples for immune-evasion factors with OB fold and β-grasp domains include the staphylococcal T cell superantigens (SEA, SEB, SEC1-3, SED, SEE, SEG, SHE, SEI, SEJ, SEK, SEL, SEM, SEN, SEO, SEP, SEQ, SER, SEU, toxic shock syndrome toxin 1 (TSST1), TSST2 and SelX) and the staphylococcal superantigen-like (SSL) family (SSL1-SSL13) 125 . Chemotaxis inhibitory protein of S. aureus (CHIPS), formyl peptide receptor-like 1 inhibitor (FLIPr), FLIPr-like (FLIPrL), extracellular adherence protein (Eap), EapH1 and EapH2 have β-grasp domains but not an OB fold 68, 146 . 
Factor Xa
The activated serine protease that cleaves prothrombin to activate the clotting cascade of vertebrates; also known as thrombokinase.
the carboxy-terminal end of the γ-chain in fibrinogen and fibrin (that is, the D domain) 96, 100, 101 (FIG. 2) . Thus, ClfA acts synergistically with Coa or vWbp in protecting staphylococci from opsonophagocytic killing, and ΔclfA mutants display defects in the pathogenesis of lethal bloodstream infections in mice 96 . Four other sortase-anchored surface proteins use their immunoglobulin-like domains to bind fibrinogen or fibrin: ClfB (which binds to the fibrinogen α-chain), fibronectin-binding protein A (FnBPA) and FnBPB (which bind to the C-terminal end of the fibrinogen γ-chain), and bone sialoprotein binding protein (Bbp; also known as SdrE isoform; which binds to the fibrinogen α-chain) 102 (FIG. 2) . These surface proteins display functional redundancy for the S. aureus agglutination pathway and contribute to the pathogenesis of bloodstream infections 103 . Purified, recombinant SSL10 has also been reported to bind human fibrinogen and fibronectin, as well as pig prothrombin and factor Xa
51
. The association of SSL10 with prothrombin and factor Xa occurs via the γ-carboxylic acid (Gla) domain and interferes with calcium-activated blood clotting but not with staphylothrombin-mediated fibrin formation 51 (FIG. 2) . ssl7 and ssl10 are not found in all S. aureus isolates 13 . Staphylokinase activates human, but not mouse, plasminogen and may solubilize coagulase-induced fibrin deposits, thereby aiding S. aureus in generating purulent lesions for dissemination to new hosts (FIG. 1b) . Of note, binding of surface proteins by fibrinogen or fibrin deposits has also been reported to influence staphylococcal interference with platelet aggregation and innate immune functions 104, 105 . In addition to their role in binding to fibrin and fibrinogen, some surface proteins have been reported to bind additional host ligands, at least in vitro. Binding to these additional host ligands, which include complement factor I (by the surface protein ClfA), fibronectin (by the surface proteins FnBPA and FnBPB), keratin 10 (by the surface protein ClfB) and loricrin (by the surface protein ClfB), may contribute to staphylococcal immune evasion, invasion of host cells or colonization of squamous epithelia 102 . fnbpA and fnbpB, which are components of the S. aureus core genome, have sequence polymorphisms, and seven isotypes with discrete antigenicity have been described 106 
Adenosine and deoxyadenosine signalling and NETosis.
Adenosine is a potent mediator of immune responses and, under physiological conditions, is synthesized following hypoxia, exposure to ROS and cell lysis associated with tissue damage. Adenosine elicits its biological effects by binding to one or more of four G protein-coupled receptors 107 : A1, A2A, A2B and A3. Adenosine receptor interaction triggers anti-inflammatory signalling cascades that inhibit platelet aggregation, neutrophil superoxide burst, neutrophil degranulation, T cell activation and release of the cytokines IL-1α and IL-10 (REF. 108 ). S. aureus increases the concentrations of extracellular adenosine during infection by expressing adenosine synthase A (AdsA), a sortase-anchored protein that catalyses the dephosphorylation of adenosine mono-, di-and triphosphates 109 (FIG. 3a) . Both ex vivo and during mouse infection, the ΔadsA mutation increases killing of staphylococci by blood neutrophils, while decreasing extracellular adenosine 109 . Thus, AdsA-mediated synthesis of adenosine promotes survival of S. aureus within neutrophils, presumably by inhibiting superoxide burst and/or degranulation 109 . Furthermore, adenosine decreases major histocompatibility complex (MHC) class II expression by macrophages and dendritic cells and dampens IL-12 production, a pivotal stimulus for T helper 1-type immune responses 107 . Staphylococcal enhancement of adenosine production may therefore interfere with T cell effector mechanisms and adaptive immune responses in infected hosts 109 . Figure 2 | Staphylococcus aureus agglutination with fibrin provides protection against phagocytes. Physiological host defences immobilize bacteria through the activation of the serine protease zymogens prothrombin (also known as factor II) and factor X (not shown). In the contact-activation pathway, surface contact results in the autocleavage of prothrombin, thereby generating thrombin (also known as factor IIa). Staphylococcus aureus superantigen-like 10 (SSL10) inhibits prothrombin autoactivation, whereas the S. aureus coagulases, coagulase (Coa) and von Willebrand factor-binding protein (vWbp) convert prothrombin to staphylothrombin. Both thrombin and staphylothrombin cleave fibrinopeptides A and B from fibrinogen to generate fibrin, which self-assembles and polymerizes into cable structures that immobilize bacteria. Thrombin activation results in the activation of additional haemostasis factors that facilitate the simultaneous attraction of phagocytes to immobilized bacteria, which is thus inhibited by SSL10 secretion. However, staphylothrombin cleaves fibrinopeptides from fibrinogen without activation of other haemostasis factors and promotes fibrin polymer assembly on the staphylococcal surface, where it protects the bacterium from neutrophils and phagocytic clearance. Fibrin agglutination on the staphylococcal surface also involves the S. aureus surface proteins clumping factor A (ClfA), fibronectinbinding protein A (FnBPA) and FnBPB, which bind to the fibrinogen γ-chains. Nature Reviews | Microbiology Pro-caspase 3 Caspase 3
Fab domains
The portions of antibodies dedicated to antigen binding.
V H 3 clan IgM
IgM derived from one of three clans of variable heavy chain (V H ) genes, the products of which provide the scaffold for the antigen-binding determinants of antibodies.
Plasmablasts
Immature B cells in the blood that secrete antibodies.
AdsA activity also modulates immune responses following the degradation of NETs. During bloodstream infection in mice, S. aureus disseminates to many different organ tissues to establish abscess lesions. These lesions are composed of a bacterial nidus, designated as the staphylococcal abscess community (SAC), encased within a pseudocapsule of fibrin deposits, and surrounded by layers of immune cells 97 . In spite of large numbers of infiltrated neutrophils, mice are unable to eliminate staphylococci from abscess lesions and eventually succumb to persistent infection 36 . Although neutro phils use NETosis to entangle staphylococci, NETs are degraded by staphylococcal nuclease (Nuc) and thereby fail to exert bactericidal activities 110 (FIG. 3b) .
Nucdigestion of NETs releases 5ʹ and 3ʹ monophosphate nucleotides that are converted by AdsA into deoxyadenosine 111 (FIG. 3b) . Deoxyadenosine production triggers caspase 3 induced apoptosis of macrophages and prevents phagocyte entry into the SAC, the core of staphylococcal abscess lesions, thereby promoting bacterial survival within the lesion 111 .
Manipulation of adaptive immune responses B cell responses. S. aureus is capable of manipulating B cell survival and function, especially through production of staphylococcal protein A (SpA), which is a sortase-anchored surface protein with high affinity for vertebrate immunoglobulin, including human IgA, IgD, IgG1-IgG4, IgM and IgE
112
. SpA is initially deposited in the staphylococcal envelope and subsequently released by cell wall hydrolases (LytM) 113 . spa is expressed by all clinical S. aureus isolates; the immunoglobulin binding domains are conserved in the genomes of these isolates, but region X, the cell wall spanning domain of SpA, is a highly polymorphic sequence 114, 115 121 . S. aureus infection in humans triggers expansions of V H 3 idiotypic plasmablasts (>90% of blood plasmablasts), the antibodies of which (that is, the B cell receptors) associate with SpA via their Fab domains but do not display pathogen-specific binding activities 121 (FIG. 4b) . When mice are treated with purified SpA, crosslinking of V H 3 clonal B cells triggers pro liferation and apoptotic collapse of expanded populations of B cells 122 . It is not clear, however, whether apoptotic collapse of expanded lymphocyte populations occurs durin g S. aureus infection in mice or in humans.
Non-toxigenic SpA, designated SpA KKAA , was engineered by substituting twenty amino acid residues essential for its association with the Fcγ and Fab regions 123 . Although SpA KKAA has twenty amino acid substitutions, this antigen elicits antibodies that neutralize SpA when + marker protein (not shown)). b | S. aureus induced NETosis of infiltrating neutrophils leads to nuclease-mediated degradation of the DNA fibres that are the major components of neutrophil extracellular traps (NETs) and AdsA-mediated conversion of 5ʹ-monophosphate-deoxyadenosine (dAMP) into deoxyadenosine (dAdo), which promotes autocleavage of the apoptosis factor pro-capsase 3 to caspase 3. Caspase 3 induces macrophage death, thereby protecting S. aureus against professional phagocytes. IL-12, interleukin-12; MHC II, major histocompatibility complex class II; Nuc, staphylococcal nuclease; PMN, polymorphonuclear leukocyte. T cell responses. Staphylococcal T cell superantigens bind to MHC class II molecules on the surface of antigen-presenting cells, providing antigen-independent crosslinking with T cell receptors on T helper cells 124 (FIG. 4c) . S. aureus strains have been shown to express 23 different enterotoxins and T cell superantigens 125 . Three superantigens are most frequently associated with human disease -toxic shock syndrome toxin 1 (TSST1), staphylococcal enterotoxin B (SEB) and SEC -each providing high-affinity interactions with distinct subsets of Vβ chain T cell receptors 126 . In humans with toxic shock syndrome, S. aureus secretion of TSST1 or other enterotoxins trigger expansions of cognate T cell populations, up to 30% of blood lymphocytes and nonspecific release of cytokines, preventing a focused adaptive immune response 127 . Depending on the site and severity of S. aureus infection or intoxication, superantigen-mediated activation of T cell responses may be associated with cytokine storms and toxic shock syndrome pathology 128 . Staphylococcal superantigens are also thought to interfere with antigen-specific proliferation of T cells and with antibody responses against specific subsets of staphylococcal antigens, including staphylococcal superantigens 129 . It is not yet known whether superantigens have a crucial role in the suppression of T cell responses in mice that are observed during S. aureus bloodstream infections 130 . S. aureus can also manipulate T cell responses by promoting T cell lysis. For example, δ-toxin (Hld; also known as δ-haemolysin), a member of the PSMα family, can lyse T cells 131 and has also been reported to trigger mast cell degranulation, which could be a key factor in plasmablasts, SpA crosslinking promotes somatic hypermutation and class switching from IgM antibodies to IgG antibodies, followed by the secretion of antibodies that are not specific for the S. aureus antigen. c | S. aureus secretes T cell superantigen (SAg), which crosslinks major histocompatibility complex class II antigens (MHC II) on the surface of antigen-presenting cells and T cell receptors (TCRs) on the surface of T helper (T H ) cells, triggering T cell expansion and anergy and causing cytokine storms (including interleukin-2 (IL-2), interferon-γ (IFNγ), IL-1β and tumour necrosis factor (TNF)). As a result, a T cell response specific for S. aureus antigens is not produced.
Autologous vaccine
A whole-cell killed S. aureus vaccine administered to an infected individual that was derived from the patient's isolate.
the exacerbation of S. aureus infected atopic dermatitis lesions, where histamine release is otherwise triggered by antigen-induced crosslinking of IgE bound to FcγRI receptor 132 . Hld is encrypted within the agr-regulated RNA III molecule, the regulatory arm of staphylococcal quorum-sensing 133 . Outlook S. aureus strains secrete many immune evasive molecules and, when placed under selective pressure, acquire mobile genetic elements with additional factors so that staphylococci meet the demands for invasion of host species and replication in specific anatomical niches 13 . These strategies are accomplished through factors that block phagocyte chemotaxis, complement activation, phagocytic uptake and oxidative killing, often redirecting host defences such as fibrin formation or NETosis to favour pathogen replication. Staphylococcal infection is also associated with perturbations of adaptive responses, including the disruptive proliferation of B cells and T cells, which prevents the establishment of protective immune responses. Why do S. aureus isolates acquire so many different immune evasion factors when other bacterial pathogens manage with only a small number? Addressing this question, one should consider that S. aureus maintains life-long associations with its human hosts, colonizing and reiteratively invading large segments of the population. We know of no other bacterial pathogen able to sustain a similar lifestyle. Staphylococcal capabilities of causing recurrent and reiterative infections probably rely on two mechanisms. First, S. aureus manipulation of B cell and T cell responses must be successful, as increased age is not associated with decreased incidence. Second, mobile genetic elements enable acquisition and/or exchange of immune evasive traits between S. aureus strains and horizontal gene transfer may implement disease in individuals who did mount successful immune responses against immune evasion determinants. If pressed to predict the future of S. aureus as it evolves with a population whose lifespan continues to increase, we would forecast more invasion by mobile genetic elements and more immune evasion determinants.
Considering the formidable weapons of the pathogen against the host's immune defences, development of vaccines against S. aureus is a daunting task.
Conventional approaches for vaccine development follow the mantra of eliciting specific antibodies that trigger pathogen killing in vitro and disease protection in preclinical (animal) models of staphylococcal disease. The simplest means of achieving these goals are whole-cell vaccines, either killed or attenuated preparations. Indeed, use of an autologous vaccine for individuals with recurrent S. aureus infection has been practised for many years 134 . This approach can elicit pathogenspecific antibodies; however, it has not been demonstrated to raise protective immunity 135 . Live-attenuated vaccines have been studied in animal models with variable success but not in humans. If one considers that the immune-evasive strategies are often species specific, it seems risky to derive claims on human protective immune responses against S. aureus from experiments with animals. What is true for whole-cell vaccines certainly applies to subunit vaccines. Antibodies against capsular polysaccharide, ClfA, IsdB and lipoteichoic acid bind to the surface of the pathogen, which enables phagocyte-mediated killing in vitro and provides protection from infection in specific animal models; however, the corresponding vaccines or antibodies did not achieve efficacy in clinical trials [136] [137] [138] . It occurred to us that in vitro assays for phagocytic killing of S. aureus often do not consider key evasion strategies of the pathogen and the corresponding defences of humans. We believe this can be addressed with Lancefield's assay for antibody-mediated killing of bacteria in fresh anti-coagulated human blood 139 . The Lancefield assay can also be used for prospective studies in humans, assessing antibody titres, status of immunity (bactericidal activity of blood) and probability of disease. This approach may identify criteria for protective immunity, stratify patients at risk for S. aureus disease and guide applications for immune-therapy or vaccination that reduce the incidence of disease. Previous work targeted B cell and T cell superantigens from S. aureus as vaccine antigens to enable the development of broad-spectrum immune responses during each encounter of the host with this pathogen 123, 140 . Another promising approach exploited the structural relatedness of immune evasion factors to target multiple molecules with antibodies that recognize conserved structural features 141 
. Nonetheless, the efficacy of these approaches has not yet been assessed in human clinical trials.
